Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.46 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.46 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.46 |
| ▸ | P2RY12 known ✓ | Q9H244 | 1/20 | 0.46 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.44 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.44 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.44 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 4/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954553 | 0.99 | DRD1 (0.47) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL1269320 | 0.99 | DRD1 (0.47) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL3077710 | 0.98 | DRD1 (0.46) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL3077705 | 0.98 | DRD1 (0.46) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL6615615 | 0.97 | DRD1 (0.45) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Sulfuric Acid SCHEMBL951856 | 0.95 | ABCB11 (0.50) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Sulfuric Acid SCHEMBL6363639 | 0.95 | ABCB11 (0.50) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Sulfuric Acid SCHEMBL6363645 | 0.93 | ABCB11 (0.48) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Sulfuric Acid SCHEMBL6375982 | 0.93 | ABCB11 (0.48) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL5024497 | 0.87 | ABCB11 (0.42) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1837337-B1 | Novel crystalline polymorphs of clopidogrel | GENERICS UK LTD (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-7897613-B2 | Crystalline polymorphs of clopidogrel | GENERICS [UK] LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| EP-1618113-B1 | NOVEL CRYSTALLINE POLYMORPHS OF CLOPIDOGREL | GENERICS UK LTD (GB) | 2010-11-10 | — | — | EP | disclosed |
| EP-2149578-A1 | Novel crystalline polymorphs of clopidogrel | Merck Generics (UK) Limited (GB) | 2010-02-03 | — | — | EP | disclosed |
| US-20070281964-A1 | Novel Crystalline Polymorphs of Clopidogrel | GENERICS [UK] LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1837337-A1 | Novel crystalline polymorphs of clopidogrel | Merck Generics (UK) Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| EP-1772456-A1 | Novel crystalline polymorphs of clopidogrel | Generics (UK) Limited (GB) | 2007-04-11 | — | — | EP | disclosed |
| EP-1618113-A1 | NOVEL CRYSTALLINE POLYMORPHS OF CLOPIDOGREL | Generics (UK) Limited (GB) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005026174-A1 | NOVEL CRYSTALLINE POLYMORPHS OF CLOPIDOGREL | GENERICS [UK] LIMITED (GB) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281964-A1 | Novel Crystalline Polymorphs of Clopidogrel | PDGFRB, PLAT, PTAFR | ADRA2A 523/4885CHRM2 582/4885SLC6A4 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.